VCM
AVIR icon

Versant Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Versant Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
+4,220
New +$21K ﹤0.01% 1939

Other funds holding AVIR

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
CAC
Certified Advisory Corp Altamonte Springs, Florida $1.24B AUM 21.71% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management's AVIR Position: Q2 2026 in Review

Versant Capital Management opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 4,220 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #1939 among its holdings.

8 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Versant Capital Management held 4,220 shares of Atea Pharmaceuticals worth $19.6K as of Q2 2026.
  • Atea Pharmaceuticals was a new Versant Capital Management position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1939 holding.
  • 8 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.